{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:30:58Z","timestamp":1773923458275,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T00:00:00Z","timestamp":1354752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2013,2]]},"abstract":"Abstract<\/jats:bold><\/jats:title>H<\/jats:styled-content>ydroxychloroquine (HCQ<\/jats:styled-content>) is generally used to treat systemic lupus erythematosus (SLE<\/jats:styled-content>) in Western countries. However, chloroquine retinopathy became a problem in Japan, and chloroquine has never been used since then. Even now HCQ<\/jats:styled-content> remains non\u2010approved. Therefore, the J<\/jats:styled-content>apanese H<\/jats:styled-content>ydroxychloroquine S<\/jats:styled-content>tudy G<\/jats:styled-content>roup has been organized, and activities have started to have HCQ<\/jats:styled-content> approved within Japan. In the present study, we investigated the effectiveness of HCQ<\/jats:styled-content> against the skin manifestations of lupus erythematosus. There were seven patients, all female, and they consisted of four patients with SLE<\/jats:styled-content> (skin lesion type: discoid lupus erythematosus [DLE<\/jats:styled-content>] in three, subacute cutaneous lupus erythematosus in one and lupus erythematosus profundus in one), two patients with cutaneous lupus erythematosus (both DLE<\/jats:styled-content>), and one patient with a combination of SLE<\/jats:styled-content> and dermatomyositis. HCQ<\/jats:styled-content> was effective in three patients and ineffective in the two patients. We could not judge the efficacy of HCQ<\/jats:styled-content> in the other two patients. There were no adverse effects in any of the patients. Efficacy was exhibited against telangiectasia and erythema. HCQ<\/jats:styled-content> is also an effective and safe treatment for Japanese patients, and it is hoped that it will be approved for use in J<\/jats:styled-content>apan very soon.<\/jats:p>","DOI":"10.1111\/1346-8138.12005","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T09:50:16Z","timestamp":1354787416000},"page":"94-97","source":"Crossref","is-referenced-by-count":14,"title":["Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus"],"prefix":"10.1111","volume":"40","author":[{"given":"Yoko","family":"Momose","sequence":"first","affiliation":[{"name":"Department of Dermatology St Luke's International Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Dermatology St Luke's International Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Dermatology St Luke's International Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology St Luke's International Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology St Luke's International Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.018"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20097"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20133"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678646137"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0503-y"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01448.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03006.x"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.12005","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.12005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:04:40Z","timestamp":1700647480000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.12005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/1346-8138.12005"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.12005","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,6]]}}}